Legislators should help manufacturing rebound
While the South Coast is reveling in its waterfront makeover, tri-county tourism is getting stronger and economists are heralding a boom in craft spirits, the manufacturing core of the region is looking more and more hollowed-out. Large sections of Simi Valley and west Ventura County and North Santa Barbara County are losing head-of-household jobs. San Read More →
Amgen seeks to market osteoporosis drug in Japan
Thousand Oaks biotech giant Amgen is seeking marketing approval in Japan for osteoporosis drug romosozumab, the company announced on Dec. 20. Amgen submitted the request to the Pharmaceuticals and Medical Devices Agency in Japan, where an estimated 12 million people have a high risk of bone fracture. The company is co-developing the drug worldwide with Euronext Read More →
Tri-county companies self-insure employee health care coverage
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Presidential election creates Central Coast winners and losers
After euphoria comes reality. The stock market rally that accompanied the election of Donald J. Trump as the nation’s 45th president has flattened out amid the reality that governing is complex and so is the economy. With Trump’s election, the slow growth predictability of the Obama years has been replaced with something new. But aside Read More →
Amgen’s Humira biosimilar delayed, Enbrel approved
Amgen’s Humira biosimilar Amjevita will be delayed at least through 2017 due to litigation by competitor AbbVie. The maker of Humira filed a patent infringement claim against Amgen on Aug. 4, alleging that the drug also violates the Biosimilar Price Competition and Innovation Act. Amgen was approved to market its biosimilar Sept. 23 by the Read More →
Joens: A fond farewell to the tri-county technology scene
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen beats analysts’ revenue, earnings per share estimates
Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →
